Sex-related differences in serum matrix metalloproteinase-9 screening non-calcified and mixed coronary atherosclerotic plaques in outpatients with chest pain | springermedizin.de

Springer Medizin

nach oben

Heart and Vessels

Erschienen in:

19.07.2017 | Original Article

Sex-related differences in serum matrix metalloproteinase-9 screening non-calcified and mixed coronary atherosclerotic plaques in outpatients with chest pain

verfasst von: Chun Gu, Fang Wang, Zhihui Hou, Bin Lv, Yang Wang, Xiangfeng Cong, Xi Chen

Erschienen in: Heart and Vessels | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study is to evaluate the clinical feasibility of serum matrix metalloproteinase-9 (MMP-9) for screening plaque composition as assessed by coronary computed tomography angiography (CCTA) in outpatients with chest pain,and the effects of sex on this feasibility. Eight hundred and sixty-two consecutive outpatients with chest pain were divided into three groups according to the results of CCTA: non-plaque (NP, n = 474), calcified plaques (CPs, n = 179), non-calcified and mixed plaques (NCPs and MPs, n = 209). We found that serum MMP-9 levels were significantly higher in patients with NCPs and MPs compared to those with either NP or CPs, especially in women (649.7 ± 279.8 vs. 485.7 ± 231.6 ng/mL or 515.7 ± 274.5 ng/mL, P < 0.001). MMP-9 showed better identification of NCPs and MPs than other related factors and was an independent predictor for NCPs and MPs both in women and men. The receiver operating characteristic analysis indicated a substantial superiority in women with area under the curve of 0.75 (95% CI 0.69–0.82, P < 0.01), compared with men of 0.59 (95% CI 0.53–0.65, z = 3.71, P < 0.01). The diagnostic tests revealed a moderate risk of the presence of NCPs and MPs with MMP-9 ≥531.6 ng/mL in female patients.

Anzeige

1.

Narula J, Nakano M, Virmani R, Kolodgie FD, Petersen R, Newcomb R, Malik S, Fuster V, Finn AV (2013) Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol 61:1041–1051CrossRefPubMedPubMedCentral

2.

Leber AW, von Ziegler F, Becker A, Becker CR, Reiser M, Steinbeck G, Knez A, Boekstegers P (2008) Characteristics of coronary plaques before angiographic progression determined by multi-slice CT. Int J Cardiovasc Imaging 24:423–428CrossRefPubMed

3.

Yamagishi M, Terashima M, Awano K, Kijima M, Nakatani S, Daikoku S, Ito K, Yasumura Y, Miyatake K (2000) Morphology of vulnerable coronary plaque: insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. J Am Coll Cardiol 35:106–111CrossRefPubMed

4.

Hou ZH, Lu B, Gao Y, Jiang SL, Wang Y, Li W, Budoff MJ (2012) Prognostic value of coronary CT angiography and calcium score for major adverse cardiac events in outpatients. JACC Cardiovasc Imaging 5:990–999CrossRefPubMed

5.

Sakaguchi M, Ehara S, Hasegawa T, Matsumoto K, Nishimura S, Yoshikawa J, Shimada K (2017) Coronary plaque rupture with subsequent thrombosis typifies the culprit lesion of non-ST-segment-elevation myocardial infarction, not unstable angina: non-ST-segment-elevation acute coronary syndrome study. Heart Vessels 32:241–251CrossRefPubMed

6.

Ehara S, Matsumoto K, Hasegawa T, Otsuka K, Sakaguchi M, Shimada K, Yoshikawa J, Yoshiyama M (2016) Characteristic patterns of the longitudinal and circumferential distribution of calcium deposits by parent coronary arteries observed from computed tomography angiography. Heart Vessels 31:508–518CrossRefPubMed

7.

Newby AC (2008) Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 28:2108–2114CrossRefPubMed

8.

Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827–839CrossRefPubMed

9.

Wang Y, Wu B, Dong L, Wang C, Wang X, Shu X (2016) Circulating matrix metalloproteinase patterns in association with aortic dilatation in bicuspid aortic valve patients with isolated severe aortic stenosis. Heart Vessels 31:189–197CrossRefPubMed

10.

Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P (1999) Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 99:2503–2509CrossRefPubMed

11.

Welgus HG, Campbell EJ, Cury JD, Eisen AZ, Senior RM, Wilhelm SM, Goldberg GI (1990) Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J Clin Investig 86:1496–1502CrossRefPubMedPubMedCentral

12.

Wagsater D, Zhu C, Bjorkegren J, Skogsberg J, Eriksson P (2011) MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr(−/−)Apob(100/100) mouse. Int J Mol Med 28:247–253PubMed

13.

Muller A, Kramer SD, Meletta R, Beck K, Selivanova SV, Rancic Z, Kaufmann PA, Vos B, Meding J, Stellfeld T, Heinrich TK, Bauser M, Hutter J, Dinkelborg LM, Schibli R, Ametamey SM (2014) Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability. Nucl Med Biol 41:562–569CrossRefPubMed

14.

Zeng B, Prasan A, Fung KC, Solanki V, Bruce D, Freedman SB, Brieger D (2005) Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 35:331–335CrossRefPubMed

15.

Leber AW, Becker A, Knez A, von Ziegler F, Sirol M, Nikolaou K, Ohnesorge B, Fayad ZA, Becker CR, Reiser M, Steinbeck G, Boekstegers P (2006) Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J Am Coll Cardiol 47:672–677CrossRefPubMed

16.

Hoffmann U, Moselewski F, Nieman K, Jang IK, Ferencik M, Rahman AM, Cury RC, Abbara S, Joneidi-Jafari H, Achenbach S, Brady TJ (2006) Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. J Am Coll Cardiol 47:1655–1662CrossRefPubMed

17.

Pundziute G, Schuijf JD, Jukema JW, Boersma E, de Roos A, van der Wall EE, Bax JJ (2007) Prognostic value of multislice computed tomography coronary angiography in patients with known or suspected coronary artery disease. J Am Coll Cardiol 49:62–70CrossRefPubMed

18.

Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, Moll F, de Vries JP, Verheijen J, Hanemaaijer R, de Kleijn DP, Pasterkamp G (2006) Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 37:235–239CrossRefPubMed

19.

Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K (2001) Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141:211–217CrossRefPubMed

20.

Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T (1998) Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32:368–372CrossRefPubMed

21.

Silvello D, Narvaes LB, Albuquerque LC, Forgiarini LF, Meurer L, Martinelli NC, Andrades ME, Clausell N, dos Santos KG, Rohde LE (2014) Serum levels and polymorphisms of matrix metalloproteinases (MMPs) in carotid artery atherosclerosis: higher MMP-9 levels are associated with plaque vulnerability. Biomarkers 19:49–55CrossRefPubMed

22.

Tan C, Liu Y, Li W, Deng F, Liu X, Wang X, Gui Y, Qin L, Hu C, Chen L (2014) Associations of matrix metalloproteinase-9 and monocyte chemoattractant protein-1 concentrations with carotid atherosclerosis, based on measurements of plaque and intima-media thickness. Atherosclerosis 232:199–203CrossRefPubMed

23.

Lehrke M, Greif M, Broedl UC, Lebherz C, Laubender RP, Becker A, von Ziegler F, Tittus J, Reiser M, Becker C, Goke B, Steinbeck G, Leber AW, Parhofer KG (2009) MMP-1 serum levels predict coronary atherosclerosis in humans. Cardiovasc Diabetol 8:50CrossRefPubMedPubMedCentral

24.

Kobayashi N, Hata N, Kume N, Yokoyama S, Shinada T, Tomita K, Kitamura M, Shirakabe A, Inami T, Yamamoto M, Seino Y, Mizuno K (2011) Matrix metalloproteinase-9 for the earliest stage acute coronary syndrome. Circ J 75:2853–2861CrossRefPubMed

25.

Gough PJ, Gomez IG, Wille PT, Raines EW (2006) Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Investig 116:59–69CrossRefPubMed

26.

Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML (2013) Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology (Bethesda) 28:391–403

27.

Newby AC (2005) Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85:1–31CrossRefPubMed

28.

Campestre C, Agamennone M, Tauro M, Tortorella P (2015) Phosphonate emerging zinc binding group in matrix metalloproteinase inhibitors. Curr Drug Targets 16:1634–1644CrossRefPubMed

29.

Li NG, Tang YP, Duan JA, Shi ZH (2014) Matrix metalloproteinase inhibitors: a patent review (2011–2013). Expert Opin Ther Pat 24:1039–1052CrossRefPubMed

30.

Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387–1397CrossRefPubMed

31.

Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H (2000) Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101:1372–1378CrossRefPubMed

32.

Koenig W, Twardella D, Brenner H, Rothenbacher D (2006) Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 26:1586–1593CrossRefPubMed

33.

Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, MacFadyen RJ (2005) Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 96:339–345CrossRefPubMed

Titel: Sex-related differences in serum matrix metalloproteinase-9 screening non-calcified and mixed coronary atherosclerotic plaques in outpatients with chest pain
verfasst von: Chun Gu
Fang Wang
Zhihui Hou
Bin Lv
Yang Wang
Xiangfeng Cong
Xi Chen
Publikationsdatum: 19.07.2017
Verlag: Springer Japan
Erschienen in: Heart and Vessels / Ausgabe 12/2017
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-017-1014-3

Anzeige

Neu im Fachgebiet Kardiologie

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen